Download App

Log in to access Online Inquiry
Company Overview More
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
CEO: Mikhail, Karim
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

AMRN Amarin
1.410-0.010-0.70%
Post Mkt Price
1.400-0.01-0.71%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-29.56% 362.56M -9.34% 454.13M -9.34% 454.13M -14.72% 479.14M
-Cash and cash equivalents
-24.69% 219.15M 17.38% 219.45M 17.38% 219.45M 7.56% 222.88M
-Short-term investments
-35.91% 143.41M -25.26% 234.67M -25.26% 234.67M -27.74% 256.27M
Receivables
-27.13% 110.23M 5.87% 163.65M 5.87% 163.65M 1.4% 149.36M
-Accounts receivable
-27.13% 110.23M 5.87% 163.65M 5.87% 163.65M 1.4% 149.36M
Inventory
15.99% 267.82M 24.26% 234.68M 24.26% 234.68M 108.22% 309.27M
Prepaid assets
-5.4% 28.09M -27.77% 22.35M -27.77% 22.35M -20.78% 21.35M
Restricted cash
0.03% 3.92M 0.08% 3.92M 0.08% 3.92M 0.05% 3.92M
Total current assets
-16.97% 772.62M -0.06% 878.73M -0.06% 878.73M 8.38% 963.03M
Non current assets
Net PPE
1.53% 9.97M -9.78% 9.09M -9.78% 9.09M -9.54% 9.33M
-Gross PPE
1.53% 9.97M -5.82% 11.01M -9.78% 9.09M -9.54% 9.33M
-Accumulated depreciation
-- -- -18.87% -1.92M -- -- -- --
Goodwill and other intangible assets
-10% 22.91M 70.42% 23.55M 70.42% 23.55M 70.58% 24.18M
-Other intangible assets
-10% 22.91M 70.42% 23.55M -- -- 70.58% 24.18M
Investments and advances
11.24% 26.7M -43.98% 35M -43.98% 35M -15.82% 38.8M
Other non current assets
30932.46% 141.51M 28073.61% 121.71M 28073.61% 121.71M -57.54% 456K
Total non current assets
236.63% 201.09M 118.16% 189.34M 118.16% 189.34M 1.55% 72.77M
Total assets
-1.67% 973.71M 10.56% 1.07B 10.56% 1.07B 7.87% 1.04B
Liabilities
Current liabilities
Payables
-3.72% 90.75M 8.54% 114.92M 8.54% 114.92M -40.33% 72.42M
-accounts payable
-3.72% 90.75M 8.54% 114.92M 8.54% 114.92M -40.33% 72.42M
Current accrued expenses
-9.23% 207.62M 22.17% 207.51M 27.42% 253.11M 52.75% 289.68M
Current deferred liabilities
-20.74% 2.2M -9.47% 2.65M -9.47% 2.65M -53.63% 2.65M
Other current liabilities
-- -- 58.42% 45.6M -- -- -- --
Current liabilities
-7.73% 300.57M 20.57% 370.68M 20.57% 370.68M 11.82% 364.75M
Non current liabilities
Long term debt and capital lease obligation
15.34% 10.4M -6.3% 8.58M -6.3% 8.58M -5.68% 8.73M
-Long term capital lease obligation
15.34% 10.4M -6.3% 8.58M -6.3% 8.58M -5.68% 8.73M
Non current deferred liabilities
-6.96% 14.14M -10.48% 14.06M -10.48% 14.06M 9.75% 14.49M
Other non current liabilities
32.33% 7.49M 23.08% 7.65M 23.08% 7.65M 24.33% 5.35M
Total non current liabilities
7.21% 32.03M -2.54% 30.28M -2.54% 30.28M 6.76% 28.57M
Total liabilities
-6.48% 332.6M 18.45% 400.97M 18.45% 400.97M 11.44% 393.31M
Shareholders'equity
Share capital
0.69% 294.36M 1.35% 294.03M 1.35% 294.03M 0.04% 293.14M
-common stock
0.69% 294.36M 1.35% 294.03M 1.35% 294.03M 1.93% 293.14M
Retained earnings
-1.55% -1.45B 0.54% -1.42B 0.54% -1.42B -0.14% -1.44B
Paid-in capital
1.62% 1.86B 2.07% 1.86B 2.07% 1.86B 2.56% 1.85B
Less: Treasury stock
5.02% 61.26M 18.88% 60.73M 18.88% 60.73M 17.49% 59.6M
Total stockholders'equity
1.02% 641.11M 6.31% 667.1M 6.31% 667.1M 5.8% 642.5M
Total equity
1.02% 641.11M 6.31% 667.1M 6.31% 667.1M 5.8% 642.5M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%